Citations

Clear

904 citation(s) found for "Gordon, S".

IC‐P‐189: REGIONAL AND VOXEL‐WISE SPATIAL RELATIONSHIPS AMONG FLUORINE‐18 AMYLOID PET TRACERS AND PITTSBURGH COMPOUND B
Adedokun, Adedamola, Marple, Laura M., Chen, Gengsheng , Hornbeck, Russ C. , Soucy, Jean‐Paul , Noto, Richard B., Jiménez‐Velázquez, Ivonne Z. , Gauthier, Serge , Surti, Ghulam M., Farlow, Martin R. , Salloway, Stephen , Flores, Shaney , Su, Yi , Gordon, Brian A. , Wang, Qing , Jack, Clifford R. , Roberson, Erik D. , Brooks, William S. , Hsiung, Ging‐Yuek Robin , McDade, Eric , Bateman, Randall J. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2019.06.4304 Get It

P3‐426: REGIONAL AND VOXEL‐WISE SPATIAL RELATIONSHIPS AMONG FLUORINE‐18 AMYLOID PET TRACERS AND PITTSBURGH COMPOUND B
Adedokun, Adedamola, Marple, Laura M., Chen, Gengsheng , Hornbeck, Russ C. , Soucy, Jean‐Paul , Noto, Richard B., Jiménez‐Velázquez, Ivonne Z. , Gauthier, Serge , Surti, Ghulam M., Farlow, Martin R. , Salloway, Stephen , Flores, Shaney , Su, Yi, Gordon, Brian A. , Wang, Qing , Jack, Clifford R. , Roberson, Erik D. , Brooks, William S. , Hsiung, Ging‐Yuek Robin , McDade, Eric , Bateman, Randall J. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3460 Get It

Trends in Multiple Myeloma Incidence in the United States (US): Demographic and Geographic Considerations and Focus on Young Adults
Ruan, Gordon , Hashmi, Shahrukh K. , Kapoor, Prashant , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

Blood | October 14, 2019 | Volume: 132 | Issue: Supplement 1 | Pages: 5575-5575

10.1182/blood-2018-99-114105 Get It

Abstract Background: The incidence of multiple myeloma (MM) in the US is increasing among non-Hispanic (NH) White males and females as well as NH Black males (Costa LJ, Blood Advances 2017). However, more specific incidence studies accounting for geographic and age subgroups are limited. There is also a growing concern that incidence of many cancers is increasing in the younger population. Utilizing the Surveillance, Epidemiology, and End Results Program (SEER), we investigated the trends in MM incidence in the US according to demographic and geographic subgroups with a focus on the young adults. Methods: Incidence rates (case/100,0000) were calculated using SEER*Stat and 2000-2015 data from SEER-18 registries age-adjusted to the U.S. 2000 standard population. We calculated the annual percentage change (APC) of incidence rates according to age groups and stratified by sex, race, and registry. Age at diagnosis was analyzed in 10-year intervals starting at 20 years. All analyses used ICD-O-3 codes 9732/3 with microscopically confirmed MM. Results: There were 69,613 MM patients included in the analysis. The mean age at diagnosis was 68 years and decreased over time from 68.5 years in 2000 to 67.6 years in 2015. Men comprised 55.5% of the population. Patients <50 years constituted 7.9% of the population with 6.6% between 40-49 years. The incidence significantly (all p values <0.01) increased from 2000-2015 for the entire cohort (incidence 6.9-9.5; APC 1.1) and for males (8.6-9.5; 1.1) and females (5.7-6.3; 0.8). The highest increase in incidence among the age groups (Figure) was in 40-49 years (1.9-2.7; 2.1). When analyzing the trends for age groups stratified by sex, women ages 40-49 years had the highest increase in incidence (1.6-2.6; 2.4). The APCs of SEER-18 registries stratified by age and sex are reported in the Table. The highest APCs (>3.0) were observed in the registries of Atlanta, Greater Georgia, Hawaii, and New Jersey. When the SEER-18 registries were further stratified by race, white men ages 40-49 years in Seattle and New Jersey had APCs of 5.5 and 2.9 respectively, while Black women ages 40-49 years in Greater Georgia had an APC of 3.3. Only 3 groups of individuals had a significant decline in the incidence: Asian women ≥70 years in Los Angeles (APC -6.4), White women ≥70 years in Los Angeles (APC -1.9), and men 50-59 years in San Jose (APC -1.5). Conclusions: The overall incidence of MM is increasing in the US with the highest increment among young adults between the age groups 40-49 years. We observed geographic and demographic differences in the incidence rates, which may reflect genetic and environmental influences. Interestingly, a few geo-demographic subgroups had a decline in the incidence. Further research is needed to determine the reasons behind the observed trends. Disclosures Kapoor: Celgene: Research Funding; Takeda: Research Funding.
Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
Rowe, Jacob M. , Buck, Georgina , Tallman, Martin S. , Richards, Susan , Burnett, Alan K. , Franklin, Ian M, Wiernik, Peter H. , Paietta, Elisabeth , Litzow, Mark R. , Marks, David I. , Luger, Selina M. , Dewald, Gordon W., Goldstone, Anthony H., Moorman, Anthony V. , Richards, Susan M, Fielding, Adele K. , Franklin, Ian M, Lazarus, Hillard M.

Mayo Clinic

Blood | October 14, 2019 | Volume: 112 | Issue: 11 | Pages: 3314-3314

10.1182/blood.v112.11.3314.3314 Get It

Abstract The International ALL trial, conducted jointly by the MRC in the UK and ECOG in the US (UKALL XII/E2993), recruited 1929 patients between 1993 and 2006. All patients aged 16 to 64 years with newly diagnosed ALL, received the identical two phases of induction therapy. Patients with an HLA-identical sibling were assigned to a sibling allogeneic transplant and those who were Ph-positive could also get an unrelated-donor transplant. Patients who did not have a donor were to be randomized between a single autologous transplant, after conditioning with etoposide/total body irradiation, versus consolidation/maintenance therapy for 2.5 years. Following randomization, but prior to receiving the assigned or randomized therapy, all patients received intensification with 3 cycles of high-dose methotrexate. After excluding patients assigned to an allogeneic transplant, 1028 patients were eligible for randomization but, as in other major transplant studies, only 457 were randomized. The rationale underlying the randomization was based on the fact that protracted consolidation/maintenance therapy in adults, extrapolated from the pediatric experience, had never been prospectively evaluated in the era of intensive chemotherapy. Given that the mortality from autotransplant is not higher than chemotherapy (Goldstone et al. Blood. 2008), it was postulated that if a single autologous transplant is at least as good as standard protracted chemotherapy that may make it the preferable option, except possibly in females in whom fertility may be an issue. The overall survival and the event-free survival were significantly superior among the chemotherapy patients (p = .05) as previously reported (Goldstone et al. Blood. 2008). Because the literature contains reports suggesting a trend in favor of autologous transplantation in some patients with ALL (Dhédiu et al. Leukemia, 2006), an analysis was performed to see if any subgroup of patients could be identified in whom: 1. chemotherapy may not be superior to autologous transplant and 2. autologous transplant may be superior. The table lists a detailed analysis of overall survival looking at various age groups, B- versus T-lineage, the rapidity with which a complete remission was achieved –after phase I or only after phase II of induction. Detailed analysis was also performed by cytogenetics looking at those with standard risk versus those with high risk abnormalities [ t(9;22), t(4;11), t(8;14)] and low hypodiploidy/near triploidy or a complex karyotype (Moorman et al. Blood. 2007)]. In all groups, the chemotherapy group was at least as efficacious as the autograft group, and in some was even significantly superior to autologous transplantation. There is no evidence that other risk factors, such as relapse rate or treatment-related mortality, influenced these overall survival data. In addition, the tests for heterogeneity were not significant across any group. In conclusion, the overall survival was longer in patients randomized to chemotherapy, although the superiority was not statistically significant in most of the groups. There is no clinical indication for autologous transplantation at any age and particularly this should not be considered for patients over age 50, those with high-risk cytogenetics or T-lineage, and late remitters, for whom it might appear most attractive. Overall Survival (OS) at 5 years in 457 Randomized Patients Chemo Auto Subgroups n OS n OS P (log rank) Age (years) < 20 50 58% 43 46% > 0.1 20–29 61 52% 70 43% > 0.1 30–39 46 39% 46 32% > 0.1 40–49 38 31% 35 31% > 0.1 50 + 33 38% 35 31% > 0.1 B-lineage 169 46% 158 35% 0.03 T-lineage 45 54% 54 49% > 0.1 Time to CR phase I 193 48% 190 41% 0.1 phase II 26 36% 29 19% 0.08 Cytogenetics standard-risk 109 51% 122 44% > 0.1 high-risk 29 23% 27 7% 0.02
The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience
Höchster, Howard S. , Gascoyne, Randy D. , Morrison, Vicki A., Fisher, Richard I., Stiff, Patrick J. , Cheson, Bruce D. , Crump, Michael , Horning, Sandra J., Hong, Fangxin , Habermann, Thomas M. , Gordon, Leo I. , Bartlett, Nancy L. , Kahl, Brad S.

Mayo Clinic

Blood | October 14, 2019 | Volume: 122 | Issue: 21 | Pages: 3060-3060

10.1182/blood.v122.21.3060.3060 Get It

Abstract Introduction The role of body mass index (BMI) impacting clinical outcome among lymphoma patients is controversial. Two recent studies suggest that increased BMI is associated with significantly improved survival. In this study the association between BMI at study entry and failure-free survival (FFS) and overall survival (OS) was evaluated in three phase III Eastern Cooperative Oncology Group-led trials, among patients with DLBCL (E4494), follicular lymphoma (FL) (E1496) and Hodgkin's lymphoma (HL) (E2496). Patients and Methods 537 patients with DLBCL, 730 patients with HD and 282 patients with FL were included in the analysis. BMI was calculated as weight (kilograms) divided by the square of height (meters), using data at study entry. BMI was analyzed both as continuous and categorical variables (underweight <18.5 kg/m2, normal weight: 18.5 to < 25 kg/ m2, overweight: 25 to < 30 kg/ m2, and obese :≥ 30 kg/ m2).The underweight group was excluded due to low (< 2%) prevalence. Baseline patient and clinical characteristics, treatment received and clinical outcomes were compared across BMI categories. PFS was defined as the time from study entry to relapse, progression, or death. OS was measured from study entry to death of any cause. The log-rank test and Cox regression models was used to check the association. The association between BMI and FFS/OS was also independently assessed among patients treated with rituximab. A sensitivity analysis was performed excluding patients with significant weight loss at baseline. Results Among patients with DLBCL, HL and FL, the median age was 70, 33 and 56; 29%, 29% and 37% were obese and 38%, 27% and 37% were overweight, respectively. Age was significantly different among BMI groups in all three studies. Higher BMI groups tended to have better prognosis at study entry among DLBCL and HL patients. BMI was not associated with clinical outcome, with p-values of 0.89, 0.30 and 0.40 for FFS, and p-values of 0.64, 0.67 and 0.09 for OS, for patients with DLBCL, HL and FL, respectively (Figure 1). In multivariate analysis adjusting for other clinical factors, BMI remains an insignificant predictor for all three histologies (Table 1). When limiting to patients treated with rituximab, the association remains non-significant for both FL patients (p=0.92 for PFS, p=0.36 for OS) and DLBCL patients (Figure 2). A subset analysis of males with DLBCL treated on R-CHOP, which matched the study cohort used in a recent report (Carson et al, 2012), revealed no differences in FFS (p=0.48) or OS (p=0.58) (Figure 2). Sensitivity analysis excluding patients with weight loss at study entry resulted in similar findings. Conclusion BMI was not significantly associated with clinical outcomes among patients with DLBCL, HL or FL, in three prospective phase III clinical trials. The findings contradict some previous reports of similar investigations. Further work is required to understand the observed discrepancies. Disclosures: Horning: Genentech: Employment.
Highly Sensitive Fluorescence In Situ Hybridization Method to Detect Double BCR/ABL Fusion and Monitor Response to Therapy in Chronic Myeloid Leukemia
Dewald, Gordon W., Wyatt, William A., Juneau, Amy L., Carlson, Richard O., Zinsmeister, Alan R., Jalal, Syed M., Spurbeck, Jack L., Silver, Richard T.

Mayo Clinic

Blood | October 14, 2019 | Volume: 91 | Issue: 9 | Pages: 3357-3365

10.1182/blood.v91.9.3357 Get It

Abstract We investigated a new method using fluorescence in situ hybridization and DNA probes that span the common breakpoints of t(9;22)(q34;q11.2) and that detect double BCR/ABL fusion (D-FISH) in bone marrow cells with this translocation, one on the abnormal chromosome 9 and one on the Philadelphia chromosome (Ph chromosome). D-FISH patterns were abnormal in 30 of 30 specimens with classic, simple, complex, and masked Ph chromosomes. Based on 200 nuclei from each of 30 normal specimens, the mean percentage of false-positive cells was 0.25 ± 0.39. Thirty-seven specimens from 10 patients were studied before treatment and two or more times at 4-month intervals after treatment with interferon-α2b (IFN-α2b) with or without ara-C. Based on 200 nuclei, the results of D-FISH in these specimens correlated closely with quantitative cytogenetics and accurately quantified disease within a few percent. We studied 6,000 nuclei for each of six specimens, three normal and three from patients with chronic myeloid leukemia (CML) in cytogenetic remission. The normal cutoff for 6,000 nuclei was 0.079% and patients in cytogenetic remission had residual disease ranging from 7 (0.117%) to 53 (0.883%) Ph-positive nuclei. We conclude that D-FISH can detect the Ph chromosome and its variant translocations and accurately quantify disease in CML at diagnosis and at all times after treatment, including cytogenetic remission.
A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia
Wyatt, William A., Zinsmeister, Alan R., Dietz‐Band, Jeanne, Silver, Richard T. , Dewald, Gordon W., Buño, Ismael

Mayo Clinic

Blood | October 14, 2019 | Volume: 92 | Issue: 7 | Pages: 2315-2321

10.1182/blood.v92.7.2315 Get It

Abstract Using a highly sensitive fluorescence in situ hybridization method with probes for BCR and ABL1 (D-FISH), we studied 37 paired sets of bone marrow and blood specimens, collected within 24 to 96 hours of each other, from 10 patients before and during treatment for chronic myeloid leukemia (CML). The normal range for 500 interphase nuclei was ≤4 (≤0.8%) nuclei based on 10 bone marrow and 10 blood specimens from normal individuals. The percentage of neoplastic nuclei was usually lower in blood than bone marrow. However, changes in the percentage of neoplastic nuclei in blood and bone marrow tracked closely over the course of therapy and with the results of quantitative cytogenetic studies on bone marrow. This result indicates that D-FISH is useful to test blood from patients with CML to monitor therapy. Moreover, by analysis of 6,000 nuclei with D-FISH, residual disease was identified in bone marrow and blood for patients in complete cytogenetic remission. Consequently, D-FISH analyses of interphase nuclei from blood could substitute for Q-cytogenetic studies on bone marrow. Thus, it may not be necessary to collect bone marrow samples so frequently to monitor therapy in CML.
Calcium Isotopic Composition and Its Association With Multiple Myeloma Disease Activity
Channon, M. B., Skulan, Joseph L., Gordon, Gwyneth W. , Monge, Jorge , Wu, Qing Feng , Anbar, Ariel D. , Fonseca, Rafaël

Mayo Clinic

Blood | October 14, 2019 | Volume: 122 | Issue: 21 | Pages: 3157-3157

10.1182/blood.v122.21.3157.3157 Get It

Abstract Multiple myeloma (MM) is characterized by clonal proliferation of a neoplastic plasma cell and its production of a monoclonal immunoglobulin; evolving from an asymptomatic pre-malignant stage named monoclonal gammopathy of undetermined significance (MGUS). At the time of diagnosis with MM, lytic lesions are present in approximately 70-80% of patients. Lytic lesions increase the risk for skeletal related events as well as treatment costs, while lowering quality of life and overall survival. Metastatic bone surveys underestimate bone disease since plain radiographs demonstrate abnormalities until at least 30% of trabecular bone has been lost and cannot provide information about ongoing bone remodeling. Bone scintigraphy lacks usefulness in following bone disease due to decreased osteoblast activity in MM, while Dual-energy X-ray absorptiometry scans produce heterogeneous local bone mineral density changes and are not recommended to evaluate bone disease in these patients. Biomarkers (eg, N- and C-terminal telopeptides of type I collagen) have been used to assess bone metabolism balance (BMB; ie, the difference between bone formation and resorption) in MM prior and subsequent to specific therapies, however, consensus is still lacking and their clinical utility is uncertain. Calcium in nature consists of six isotopes, and the relative abundance of the isotopes varies measurably. The strength of molecular bonds depends on atomic weight of the participating atoms. Calcium (Ca) containing compounds react at different rates depending on atomic mass. Bone formation favors lighter isotopes of Ca, depleting soft tissue of light Ca isotopes, while bone resorption releases this isotopically light Ca back into soft tissue with little or no selectivity. As a result of this difference in isotope fractionation, Ca isotopic composition in soft tissue should shift to heavier Ca isotope values in positive BMB and lighter values in negative BMB. In order to identify whether Ca isotopic composition can be used as a marker of myeloma-induced bone disease, we first set out to determine its association with MM disease activity. Using multiple collector inductively coupled plasma mass spectrometry, we determined the Ca isotopic composition in 108 peripheral blood samples from 54 patients with monoclonal gammopathies. Ca isotopic composition was determined as the ratio between the naturally occurring 44Ca and 42Ca isotopes (δ44/42Ca) relative to a standard in parts per ten thousand units, as previously described by Morgan et al. Disease activity was determined at the time of δ44/42Ca determination by assessing disease status and response to treatment, as described by the International Myeloma Working Group uniform response criteria, defining progressive or relapsed disease as active disease, and stable or responsive disease as non-active. Categorical variables were analyzed using chi squared or Fisher’s exact test, interval variables were analyzed using a one-tailed t-test. A repeated measures logistic regression model was developed using a cross-sectional time-series generalized estimating equation. All statistical analysis was done using Stata/SE 12.0. Fifty-four adult patients (61% male) diagnosed with monoclonal gammopathy, ranging from MGUS (n=1) to SMM (n=4) to MM (n=49), were assessed at different time points, with 7 patients being assessed once, 41 were assessed twice, 5 were assessed 3 times, while 1 patient was assessed 4 times. Mean age at the time of first assessment was 66, ranging from 45 to 84. Mean δ44/42Ca was statistically lower in the active disease group as compared to the non-active group (-0.7536 vs -0.6564, p=0.0466). In a statistically significant repeated measurement logistic regression model (p= 0.0239), δ44/42Ca is associated with active disease (OR=0. 054, p=0.031, 95% CI=0.004-0.765) after adjusting for age, gender, presence of anemia, serum creatinine, free light chain ratio, current bisphosphonate and current anti-myeloma therapy. A lower δ44/42Ca in the active disease group might suggest a link between a more intense level of bone resorption and myeloma activity. Ca isotopic composition can become part of the clinician’s arsenal to determine disease status in a patient with MM. In order to further characterize δ44/42Ca to specifically infer myeloma-induced bone disease activity, further studies that include serum biomarkers and dynamic imaging should be performed. Disclosures: Gordon: Arizona State University: “Application of Ca isotope analysis to the early detection of metastatic cancer” (AzTE reference number M13-117) Patents & Royalties; Arizona State University: “Isotopic biomarkers for rapid assessment of bone mineral balance in biomedical applications” (US Application #PCT/US2011/039780; AzTE reference number M10-102L), “Isotopic biomarkers for rapid assessment of bone mineral balance in biomedical applications” (US Application #PCT/US2011/039780; AzTE reference number M10-102L) Patents & Royalties. Skulan:AZTE: “Application of Ca isotope analysis to the early detection of metastatic cancer” (AzTE reference number M13-117) Patents & Royalties; AZTE: “Isotopic biomarkers for rapid assessment of bone mineral balance in biomedical applications” (US Application #PCT/US2011/039780; AzTE reference number M10-102L), “Isotopic biomarkers for rapid assessment of bone mineral balance in biomedical applications” (US Application #PCT/US2011/039780; AzTE reference number M10-102L) Patents & Royalties. Anbar:Arizona State University: “Isotopic biomarkers for rapid assessment of bone mineral balance in biomedical applications” (US Application #PCT/US2011/039780; AzTE reference number M10-102L), “Isotopic biomarkers for rapid assessment of bone mineral balance in biomedical applications” (US Application #PCT/US2011/039780; AzTE reference number M10-102L) Patents & Royalties; Arizona State University: “Application of Ca isotope analysis to the early detection of metastatic cancer” (AzTE reference number M13-117) Patents & Royalties. Fonseca:AMGEN: Consultancy; Millennium: Consultancy; Binding Site: Consultancy; Onyx: Consultancy, Research Funding; Lilly: Consultancy; BMS: Consultancy; Genzyme: Consultancy; Celgene: Consultancy; Medtronic: Consultancy; Otsuka: Consultancy; Cylene: Research Funding; Prognostication of MM based on genetic categorization of the disease: Patents & Royalties.
Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis
Evens, Andrew M. , Lossos, Izidore S. , Hernandez‐Ilizaliturri, Francisco J. , Robinson, Barrett K., Otis, Stevie, Dagan, Liat Nadav, Abdallah, Ramsey, Kroll, Aimee, Sandoval, José , Yarber, Jessica Lee, Foyil, Kelley V., Parker, Linda, Leonard, John P., Evens, Andrew M , Advani, Ranjana H. , Press, Oliver W. , Vose, Julie M. , Sandoval, Jose, Gordon, Leo I. , Habermann, Thomas M. , Bartlett, Nancy L.

Mayo Clinic

Blood | October 14, 2019 | Volume: 118 | Issue: 21 | Pages: 94-94

10.1182/blood.v118.21.94.94 Get It

Abstract Abstract 94 Background: Lymphoma diagnosed during pregnancy is a rare occurrence. Further, there is heterogeneity in clinical presentation and a range of lymphoma histologies resulting in a continued deficiency of lymphoma-specific data in the literature regarding prognosis, optimal therapy, maternal complications, and fetal outcome. Methods: A comprehensive retrospective analysis was completed for patients (pts) diagnosed (dx) with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) during pregnancy at 9 large U.S. academic centers over a 13-year period (1998–2011). The vast majority of cases were co-managed with high-risk maternal fetal medicine. Data on maternal disease characteristics, treatment details, obstetric complications, and fetal outcomes were analyzed. Results: 88 cases were identified with complete data available in 82. The median age of pts was 31 yrs (18–40). Lymphoma dx occurred at a median of 24 weeks (wks) gestation (5–40). 15% of pts were dx during the 1st trimester, 46% during the 2nd trimester, 35% during the 3rd trimester, while 4% (n=3) of pts had a pre-existing NHL dx (follicular lymphoma (FL)). 52% (n=43) of pts had NHL and 48% (n=39) HL. Of NHL cases, 83% (n=33) were B-cell and 17% (n=10) T-cell. B-cell histologies were DLBCL n=23 (including 2 primary CNS and 1 'double hit' NHL), FL n=5 (including 1 leukemic phase FL), Burkitt's lymphoma n=3, and mixed histology n=1; T-cell histologies were anaplastic large cell n=6, PTCL not otherwise specified n=2, and T-cell/NK NHL n=2. Pts with B-cell NHL and HL were dx at a median age of 29 yrs (range, 18–40), while T-cell NHL pts were dx at a median of 34 years (19–37). MRI without gadolinium was the most common imaging modality utilized for staging. 63% of NHL and 19% of HL pts had stage III/IV disease (25% of HL with stage IIB). Pregnancy was terminated in 6 pts (n=4 aggressive NHL and n=2 HD) to enable immediate chemotherapy (five in the 1st trimester [at 5, 8, 10, 10, and 12 wks] and 1 pt in the early 2nd trimester who required high-dose methotrexate). 48 pts (63%) initiated anti-lymphoma therapy at a median of 25 wks gestation (range, 13–37) with 79% of pts initiating therapy in the 2nd trimester (see Table 1). The median gestation at time of lymphoma dx for pts who received intra-partum treatment was 20 wks vs 34 wks for pts who had therapy deferred to post-delivery (p<0.0001). The overall response rate among pts who received therapy was 87% (74% complete remission). Notably, gestation went to full-term in 54% with delivery occurring at a median of 37 wks (31–40). Therapy was deferred until post-delivery in 28 pts (37%) and the majority of these pregnancies were also carried to term (median delivery at 38 wks). At a median follow-up of 41 months (6–157), the 3-year PFS and OS for all pts were 79% and 89% respectively. Histology-specific 3-year PFS and OS were: B-cell NHL: 73% and 82%, respectively; T-cell NHL: 50% and 90%, respectively; and HL: 90% and 95%, respectively (Figure 1). Detailed obstetrical information was available in 59 pts. There were minimal pre-term complications, the most common being induction of labor in 45%. Perinatal events included spontaneous rupture of membranes in 5% and pre-eclampsia in 8%. Further, there were no differences in these events detected among pts who received intra-partum treatment vs deferred therapy. No episodes of chorioamnionitis or endometritis were noted. There was 1 stillbirth that occurred at 19 wks gestation in a 34-year-old pt with double-hit NHL following 1 cycle of R-CHOP. The median birth weight of infants was 2427 grams (1005–5262) with no difference among pts who received intra-partum chemotherapy vs not (2637 grams vs 2212 grams, respectively; p=NS). Microcephaly was reported in 1 case following 4 intra-partum cycles of CHOP for DLBCL; there were otherwise no malformations detected. Conclusions: To our knowledge, this represents one of the largest experiences reported of lymphoma in pregnancy. Our data show that standard NHL and HL chemotherapeutic regimens (without anti-metabolites) administered during the 2nd and 3rd trimester, including as early as 13 wks gestation in select cases, is associated with minimal maternal complications or fetal detriment. In addition, pts with low risk clinical scenarios (e.g., indolent NHL and/or late gestational dx) had therapy safely deferred to post-partum. In our experience, this approach was associated with overall expected lymphoma-related survival. Disclosures: No relevant conflicts of interest to declare.
Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.
Geyer, Susan M. , Lin, Thomas S., Call, Timothy G. , Jelinek, Diane F., Bone, Nancy D., Dewald, Gordon W., Heerema, Nyla A. , Tschumper, Renee C. , Smith, Lynne M. , Grever, Michael R. , Byrd, John C. , Byrd, John C. , Kay, Neil E. , Smith, L., Byrd, John C

Mayo Clinic

Blood | October 14, 2019 | Volume: 104 | Issue: 11 | Pages: 339-339

10.1182/blood.v104.11.339.339 Get It

Abstract The nucleoside analogue pentostatin has clinical activity in B-Cell Chronic Lymphocytic Leukemia (CLL) and has shown significant activity and minimal toxicity when combined with cyclophosphamide for previously treated CLL. Building on this, we initiated a trial in 2002 of combined pentostatin (2mg/m2), cyclophosphamide (600 mg/m2) and rituximab (375mg/m2). Of the 33 enrolled eligible patients included in these analyses, seventeen patients were in the high Rai risk group, 25 were male, and median age for this cohort was 62 yrs (range: 40–79); 17 were non-mutated for the immunoglobulin heavy chain variable region gene, and the majority (67%) were CD38 negative. Only 5 patients had no detectable chromosomal abnormalities by FISH at baseline, 20 had a single FISH anomaly, and 8 had 2 or more FISH anomalies. Of all 28 pts with any anomaly, the following specific abnormalities were detected: 13q- (n=17), +12 (n=8), 11q- (n=7), 17p- (n=2), t(14;18) (n=1), 6q- (n=1), and MDM2 (n=1). Of the 33 patients, 22 had grade 3+ toxicity; 16 patients had non-hematologic toxicity wtih the most common symptoms being nausea (6) and vomiting (4). One patient died on study of grade 5 hypoxia as well as hypotension and this was deemed possibly related to treatment. Almost all patients (32/33; 97%) had a best response of PR or better. Including review of bone marrows done 2 months post-treatment, there were 11 CRs (complete response), 7 nPRs (nodal partial response) and 13 PRs. No differences were observed between type of response and mutation status or CD38+ status. Post-treatment FISH analyses were available on 27 patients; results for 25 patients became normal after treatment. Of the remaining 2, one patient was 13q- x1 and went from 94% to 27.5% abnormal nuclei after treatment; the other is the patient who died on study. To establish minimal residual disease (MRD) post-response, we used three color flow cytometry to detect CD5+/CD19+/CD79b− B cells. This approach found all patients had a reduction in CLL B cells with a median reduction of 91% (range: 5 – 100%). Of interest, all 3 response groups (CR vs. nPR vs. PR) had patients with significant reductions in CLL B cells (i.e., >90%). The nPR group was most variable in terms of MRD (median 47%; range: 5–93%) compared to the CR (median: 91%; range: 42–99.9%) and PR (median: 97%; range: 46–100%) groups. In conclusion this novel regimen of pentostatin, cyclophosphamide and rituximab has demonstrated significant clinical activity irrespective of risk stratification parameters with rapid induction of responses, achievement of minimal residual disease in some, and modest toxicity. Patients continue to be accrued to further explore correlative measures of response to treatment.